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Abstract
Background: Antimicrobial resistance of Helicobacter pylori 
is the main reason for eradication failure. We have studied 
the feasibility of a commercial transport medium for cultural 
recovery and subsequent drug susceptibility testing.
Patients and Methods: From March to December 2000, 79 
consecutive gastric biopsies, positive in a rapid urease test, 
were transferred into a commercial transport medium and 
sent within 24 hours from the district hospital to the micro-
biological laboratory for culture and susceptibility testing. 
A commercial agar plate and an in-house Wilkins-Chalgren 
agar plate were used for culture. Susceptibility data were 
compared with data collected from 1992 to 2003 in the 
University Hospital of Zurich.
Results: Cultural recovery and susceptibility testing of 
H. pylori was successful in 55 of 79 patients. In 17 cases 
cultural recovery failed because of technical problems 
(n = 14), long transport time (n = 1) and unknown reason 
(n = 2). Failure of susceptibility testing (n = 7) was mainly 
due to fungal overgrowth. Resistance to metronidazole and 
clarithromycin was found in 15 (27%) and in 12 patients 
(22%), respectively; resistance to amoxicillin was not 
observed. Five patients (9%) showed resistance both to 
metronidazole and to clarithromycin. Eradication therapy 
failed in all patients with macrolide resistance. Resistance 
rates were higher in females than in males; 30% vs 12% 
for clarithromycin and 33% vs 20% for metronidazole. 
Resistance to metronidazole was significantly lower in Swiss 
patients (15%) than in non-Swiss patients (39%).
Conclusion: Antimicrobial resistance data can reliably be 
obtained by sending the biopsy specimen in a commercial 
transport medium to a microbiological laboratory. This is 
especially important after eradication failure. Resistance to 
metronidazole and clarithromycin is highly prevalent and 
more common in women and non-Swiss patients. 
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Introduction
Helicobacter pylori infection, now generally accepted as 
the cause of chronic gastritis and peptic ulcer disease, has 
also been linked to gastric adenocarcinoma and gastric mu-
cosa-associated lymphoid tissue (MALT) lymphoma [1]. 
Eradication of H. pylori is the first therapeutic approach 
that constitutes a reliable long-term prophylaxis of peptic 
ulcer relapse [2], accelerates ulcer healing [3], and reduces 
the rate of ulcer complications [4]. Moreover, eradication 
of H. pylori improves the quality of life of ulcer patients 
[5]. Over the past 15 years different eradication therapies 
have been promoted. The first-line therapies of choice are 
proton pump inhibitor-based triple therapies with clar-
ithromycin, metronidazole, and amoxicillin as the most 
frequently used antibiotics for curing H. pylori infection 
[1, 6]. In a European survey, drug resistances range from 
10% to 50% for metronidazole and up to 15% for clarithro-
mycin, resistance to amoxicillin appears to be uncommon 
[7]. Apart from noncompliance, antibiotic resistance is the 
major cause of eradication treatment failure. Susceptibility 
testing is frequently recommended for correct treatment 
of H. pylori infection, especially when a first treatment at-
tempt has failed [8].
H. pylori is a fastidious, microaerophilic species. Vari-
ous conditions can affect survival rates of H. pylori, e.g. 
the time lapse between sampling and culture, transport 
temperature, transport media, duration of exposure to air 
[9]. The aim of this study was to evaluate the reliability of 
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a commercial transport medium and a commercial H. py-
lori plate for cultural recovery to allow drug susceptibility 
testing of H. pylori. The antibiotic resistance data obtained 
were compared with those from the years 1992–2003 of the 
University Hospital of Zurich.
Patients and Methods
Between March and December 2,000 consecutive patients over 
age 18, who were referred for upper endoscopy to the gastro-
enterology division of the hospital Wetzikon, Switzerland, were 
included in this study. During endoscopy biopsy specimens from 
antrum and corpus were taken for rapid urease test (HUT test; 
AstraZeneca, Wedel, Germany) and culture of H. pylori. We con-
sidered a patient to be H. pylori positive when the rapid urease 
test indicated mucosal colonization. Rapid urease test positive 
gastric biopsy samples of 79 patients (37 female, 42 male; mean 
age 52.4 years) were sent to the medical microbiology laboratory 
of the University of Zurich to determine antimicrobial suscepti-
bility to metronidazole, clarithromycin, and amoxicillin. Detailed 
epidemiological data, including country of origin and medical 
history, were obtained from each patient. Nine patients had duo-
denal ulcer, two patients ventricular ulcer, ten patients erosive 
duodenitis and 12 patients erosive antral gastritis, respectively. All 
other 46 patients with a positive urease test had no pathologic en-
doscopic or histologic findings and were not treated. Patients with 
active gastric or duodenal ulcers or erosive duodenitis or antral 
gastritis or with a history of peptic ulcer disease were treated with 
a 7-day triple therapy (pantoprazol 40 mg, clarithromycin 500 mg, 
amoxicillin 1,000 mg, each twice daily), followed by a 4-week regi-
men with the proton pump inhibitor once daily. Compliance of the 
patients was surveyed by telephone interview 3 days after onset of 
eradication therapy and after the end of therapy. Then, 4 weeks 
after the end of proton pump inhibitor therapy, success of H. 
pylori eradication was determined with a 13C -urease breath test 
(Labco; High Wycombe, Buckinghamshire, UK) or, if endoscopy 
was indicated, by rapid urease test of an endoscopic biopsy.
Biopsy specimens were transported from the endoscopic unit 
to the microbiological laboratory within 24 h in a special transport 
medium (Portagerm pylori®; BioMérieux, Marcy l’Etoile, France) 
and processed immediately upon receipt. Biopsy specimens were 
removed from the transport medium and spread over the surface 
of Wilkins-Chalgren agar (in-house made) supplemented with hu-
man blood (65 ml/1,000 ml) and antibiotics (vancomycin 10 mg/l, 
cefsulodin 2 mg/l, trimethoprim 5 mg/l, actidione 100 mg/l). Plates 
were incubated for 4 days at 37 °C in a microaerophilic atmo-
sphere (90% N2, 5% CO2, 5% O2) using a gas generator (Campy 
Gen; Oxoid, Basingstoke, England). Following recognition of a 
laboratory problem with a too low content of blood in the in-house 
Wilkins Chalgren agar (33 ml instead of 65 ml/1,000 ml), we in-
cluded a commercial H. pylori plate (Pylori Agar®, BioMérieux, 
Marcy l’Etoile, France) for cultural recovery.
Translucent colonies of characteristic appearance for H. 
pylori were Gram stained for typical morphology and tested for 
catalase, oxidase, and urease activities. Susceptibility testing was 
performed using Etest (AB Biodisk, Solna, Sweden) according 
to the prescriptions of the manufacturer as described earlier [10]. 
In brief, an isolate of H. pylori was inoculated onto sheep blood 
agar plates with a suspension of MacFarland 3 and the Etest 
stripes were applied to the agar surface. Plates were incubated 
for 3 days in a microaerophilic atmosphere at 37 °C. For inter-
pretation of susceptibility we used the NCCLS breakpoint of 
≥ 1 mg/l for clarithromycin [11]; for amoxicillin and metronidazole 
the breakpoints were ≥ 2 mg/l and ≥ 8 mg/l, respectively [12]. The 
susceptibility data obtained were compared with the susceptibility 
results of the years 1992–2003 of the University Hospital of Zur-
ich, Switzerland, tested at the Institute of Medical Microbiology 
of the University of Zurich.
Statistical significance for two independent classes was as-
sessed by the ² test or Fisher's exact test if numbers smaller than 
five were present.
Results
Culture and susceptibility testing was successful in 55 of 79 
patients. Antimicrobial resistance against metronidazole 
was present in 15 strains (27%), resistance against clarithro-
B. Yuen et al.   Transport Medium for Helicobacter pylori
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Figure 1. MICs of the 55 strains of H. pylori isolated in the district 
hospital. 
mycin was found in 12 strains (22%). Five patients (9%) 
showed resistance both to metronidazole and to clarithro-
mycin. Resistance against amoxicillin was not observed. 
MICs of metronidazole, clarithromycin, and amoxicillin 
are shown in figure 1. For 25 of the 33 patients undergoing 
eradication therapy, cultural recovery was successful and 
drug susceptibility data were obtained. Eradication of H. 
pylori was successful in all patients (N=15) with susceptible 
H. pylori strains and in five of six patients with metroni-
dazole resistant strains, whereas eradication failed in two 
patients with clarithromycin-resistant strains and in two 
patients with double resistance. 13C -urease breath test in-
dicated successful eradication therapy in all eight patients 
with negative culture results. 
Geographic origin and sex of the patients were the 
main factors affecting the results of antibiotic resistance. 
In Swiss patients, metronidazole resistance was less fre-
quent (15%, n = 4), compared to non-Swiss patients (39%, 
n = 11; p < 0.05, Fisher's exact test), originating mainly 
from the Mediterranean area, e.g. Italy, Balkans, and Af-
rica. Clarithromycin resistance was present in five Swiss 
patients (19%) and in seven non-Swiss patients (25%). In 
female patients resistance against metronidazole was found 
in ten (33%) and against clarithromycin in nine (30%) 
cases, compared to five (20%) and three (12%) cases in 
male patients, respectively.
In the 1st month of the study, determination of suscep-
tibility was successful in ten of 11 isolates. Subsequently 
culture of H. pylori failed in 14 patients because two lots 
of the in-house Wilkins Chalgren agar were produced 
with an incorrect low content of human blood. During 
this period, determination of drug susceptibility was not 
successful in an additional six cases because subcultiva-
tion failed due to fungal overgrowth. Following identi-
fication and correction of the laboratory problem a new 
commercial plate, i.e. Pylori agar (BioMérieux), was 
chosen to be evaluated at the same time. In 33 cases the 
commercial plate was compared to the standard in-house 
Wilkins Chalgren agar. Culture with the commercial H. 
pylori plate was successful in 32 cases (97%), and in 29 
cases (88%) with the in-house H. pylori plate. During the 
time with correct agar plates three culture results were 
negative; once because the transport time from the endo-
scopic unit to the microbiological laboratory was too long 
(4 days) and in two cases because of unresolved reason. 
In one case subcultivation failed.
Data on antimicrobial susceptibility of H. pylori col-
lected at the University Hospital Zurich in the years 1992–
2003 are shown together with the data of the district hos-
pital in table 1. The fluctuation in the number of samples 
submitted for culture indicates nonrepresentative patient 
selection. In the years with a low number of examined 
patients, susceptibility testing was performed primarily in 
selected patients, e.g. patients after eradication therapy 
failure. Thus, the data have to be interpreted with caution. 
Nevertheless, our data indicate that resistance to clarithro-
mycin shows an increasing trend over the years.
Discussion
Isolation of H. pylori from gastric biopsy specimen is a dif-
ficult procedure that is affected by a number of factors, 
such as presence of oropharyngeal flora, time lapse be-
tween sampling and culture, inappropriate transport tem-
perature, duration of exposure to air. The present study 
indicates that survival rates of H. pylori are excellent when 
using a commercially available transport medium and cul-
B. Yuen et al.   Transport Medium for Helicobacter pylori
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 Total  Positive  Susceptibility  Metronidazole  Clarithromycin  Amoxicillin
 patients culture testing resistance resistance resistance
    (%)    (%)   (%)
1992 163   91 (56)   82 64 (78)   -   - 
1993 314 149 (47) 130 93 (72)   -   - 
1994 288 107 (37)   94 43 (46)   -   - 
1995   82   42 (51)   34 14 (41)   -   - 
1996   48   22 (45)   22  8 (36)    2 (9)    0 
1997 256   90 (35)   76 28 (36) 11 (14)   0 
1998   69   24 (34)   24 15 (62)  7 (29)   0 
1999   19    8 (42)    7  4 (57)  5 (71)   0 
2000   21   10 (48)   10  5 (50)  6 (60)   0 
2001   25   14 (56)   11  9 (82)  5 (45)   1  
2002   34   18 (53)   14  9 (64)  7 (50)   0 
2003   27   13 (48)   13  6 (46)  6 (46)   1
2000   79a   55 (70)   55b 15 (27) 12 (22)   0 
a Consecutive patients with positive rapid urease test (HUT test); b Positive culture and susceptibility testing
Table 1
Helicobacter pylori antimicrobial resistance by year in the university hospital (1992–2003) and in a district hospital (2000).
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turing within 24 h. These results are in line with earlier 
reports [13, 14]. The reliability of the transport medium is 
especially important for district hospitals or practitioners 
who have to send the biopsy specimen to an external mi-
crobiological laboratory. Due to the fastidious nature of H. 
pylori, primary isolation from biopsy specimen can be diffi-
cult. During parallel testing a commercial pylori agar plate 
was found to be superior to the in-house pylori agar.
The results of our study show antimicrobial resis-
tance rates of 22% for clarithromycin and 27% for met-
ronidazole, respectively. In a study by Maggi-Solcà et al. 
performed in the southern part of Switzerland resistance 
rates were as high as 12% for clarithromycin (13% with a 
breakpoint of 1 mg/l according to NCCLS [11]) and 29% 
for metronidazole [12]. Our epidemiological data showed 
an insignificant higher prevalence of resistant H. pylori 
strains in female compared to male patients. These data 
correspond to results of other studies [1, 15, 16]. With re-
spect to metronidazole, this may be due to treatment of 
genital tract infections (e.g. trichomoniasis, bacterial vagi-
nosis). Resistance to clarithromycin may be provoked by 
the use of erythromycin in pregnancy or by the use of mac-
rolides for chlamydial or non-gonococcal urethritis/cervici-
tis. A significant difference in metronidazole resistance was 
observed between Swiss patients (15%) and non-Swiss pa-
tients (39%), whereas there was no difference in clarithro-
mycin resistance between these two groups. In accordance 
with our results, an analysis of data from 11 European 
countries showed that rates of resistance to metronidazole 
were higher in non-white patients from northern Africa 
and Mediterranean countries than in patients from north-
ern European countries [17].
The systematic drug susceptibility testing of cultur-
ally recovered H. pylori revealed a high prevalence of re-
sistance to clarithromycin. So far only a few studies have 
examined the development of clarithromycin resistance 
in H. pylori. A study conducted in the USA by Vakil et 
al. [18] showed an increase in clarithromycin resistance 
from 4% in 1993–94 to 12.6% in 1995–96. A 9-year study 
of the evolution of clarithromycin resistance in Spanish 
children by Lopez-Brea et al. [19] showed an increase in 
clarithromycin resistance from 2.3% in 1991–93 to 21% in 
1994–96 and 28% in 1997–99. The increase in clarithro-
mycin resistance might be due to the widespread use of 
macrolides, especially for respiratory tract infections. In 
Switzerland macrolides are the second most prescribed 
antibiotics for community acquired pneumonia [20]. 
Data concerning metronidazole resistance rates are 
conflicting. A UK study by Parsons et al. [16] showed 
a significant increase in metronidazole resistance from 
1994/95 (20.8%) to 1995/96 (46.7%), but thereafter re-
sistance rates appeared to have reached a plateau. In a 
recently published US meta-analysis by Meyer et al. [15] 
metronidazole resistance tended to decrease over time. 
One reason for this apparent decrease may be a result of 
changes in susceptibility testing methods.
Although the number of patients undergoing eradica-
tion therapy was small, our study demonstrates that anti-
microbial resistance has an important impact on H. pylori 
eradication rates. All patients with susceptible H. pylori 
strains have been successfully eradicated, whereas eradica-
tion therapy failed in all patients with clarithromycin resis-
tance. Recent recommendations suggest that the optimal 
regimen for primary treatment of H. pylori is a combina-
tion of a proton pump inhibitor with two of the following 
antibiotics: amoxicillin, clarithromycin or a nitroimidazole 
(either metronidazole or tinidazole) [21]. With such triple 
therapies, cure rates of 80–85% can be achieved [22]. In the 
presence of antimicrobial resistance cure rates are mark-
edly reduced. A meta-analysis of the effect of pretreatment 
antibiotic resistance to metronidazole and clarithromycin 
on the outcome of eradication therapy showed a reduction 
of almost 40% in strains with metronidazole resistance and 
55% in strains with clarithromycin resistance [23]. In these 
patients standard triple therapy often leads to treatment 
failure with selection of H. pylori strains that have acquired 
dual resistance and are difficult to eradicate [8]. To avoid 
development of dual resistance, it was proposed not to 
combine clarithromycin and metronidazole in therapeutic 
regimens [6]. The increasing problem of antibiotic resis-
tance is a major argument to restrict H. pylori eradication 
therapy to those patients with adequate indication. Drug 
susceptibility testing should be done to prevent treatment 
failure and the emergence of multiple-resistant H. pylori 
strains [24].
In conclusion, antimicrobial resistance can be reliably 
determined in a district hospital by using the commercial 
transport medium Portagerm pylori. Resistance to metro-
nidazole and clarithromycin is highly prevalent and more 
common in women and non-Swiss patients. A continuous 
surveillance of H. pylori susceptibility to antibiotics at the 
national or regional level is needed. The role of antimi-
crobial susceptibility testing is of increasing importance 
in treating H. pylori infection, especially after eradication 
failure.
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